Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation

Author(s):  
Scott A. Rizzi ◽  
Stacey Knighst ◽  
Heidi T. May ◽  
Scott C. Woller ◽  
Scott M. Stevens ◽  
...  
2020 ◽  
Vol 103 (6) ◽  
pp. 548-552

Objective: To predict the quality of anticoagulation control in patients with atrial fibrillation (AF) receiving warfarin in Thailand. Materials and Methods: The present study retrospectively recruited Thai AF patients receiving warfarin for three months or longer between June 2012 and December 2017 in Central Chest Institute of Thailand. The patients were classified into those with SAMe-TT₂R₂ of 2 or less, and 3 or more. The Chi-square test or Fisher’s exact test was used to compare the proportion of the patients with poor time in therapeutic range (TTR) between the two groups of SAMe-TT₂R₂ score. The discrimination performance of SAMe-TT₂R₂ score was demonstrated with c-statistics. Results: Ninety AF patients were enrolled. An average age was 69.89±10.04 years. Most patients were persistent AF. An average CHA₂DS₂-VASc, SAMe-TT₂R₂, and HAS-BLED score were 3.68±1.51, 3.26±0.88, and 1.98±0.85, respectively. The present study showed the increased proportion of AF patients with poor TTR with higher SAMe-TT₂R₂ score. The AF patients with SAMe-TT₂R₂ score of 3 or more had a larger proportion of patients with poor TTR than those with SAMe-TT₂R₂ score of 2 or less with statistical significance when TTR was below 70% (p=0.03) and 65% (p=0.04), respectively. The discrimination performance of SAMe-TT₂R₂ score was demonstrated with c-statistics of 0.60, 0.59, and 0.55 when TTR was below 70%, 65% and 60%, respectively. Conclusion: Thai AF patients receiving warfarin had a larger proportion of patients with poor TTR when the SAMe-TT₂R₂ score was higher. The score of 3 or more could predict poor quality of anticoagulation control in those patients. Keywords: Time in therapeutic range, Poor quality of anticoagulation control, Warfarin, SAMe-TT₂R₂, Labile INR


2016 ◽  
Vol 32 (10) ◽  
pp. 1247.e15-1247.e21 ◽  
Author(s):  
Pak-Hei Chan ◽  
Duo Huang ◽  
Chu-Pak Lau ◽  
Esther W. Chan ◽  
Ian C.K. Wong ◽  
...  

2014 ◽  
Vol 36 (9) ◽  
pp. 1160-1168 ◽  
Author(s):  
François-Emery Cotté ◽  
Hicham Benhaddi ◽  
Isabelle Duprat-Lomon ◽  
Adam Doble ◽  
Nick Marchant ◽  
...  

2020 ◽  
Vol 9 (6) ◽  
pp. 1698 ◽  
Author(s):  
Rungroj Krittayaphong ◽  
Thoranis Chantrarat ◽  
Roj Rojjarekampai ◽  
Pongpun Jittham ◽  
Poom Sairat ◽  
...  

Background: Warfarin remains the most commonly used oral anticoagulant (OAC) in Thailand for stroke prevention among patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to investigate the relationship between time in therapeutic range (TTR) after warfarin initiation and clinical outcomes of NVAF. Methods: TTR was calculated by the Rosendaal method from international normalized ratio (INR) data acquired from a nationwide NVAF registry in Thailand. Patients were followed-up every six months. The association between TTR and clinical outcomes was analyzed. Results: There was a total of 2233 patients from 27 hospitals. The average age was 68.4 ± 10.6 years. The average TTR was 53.56 ± 26.37%. Rates of ischemic stroke/TIA, major bleeding, ICH, and death were 1.33, 2.48, 0.76, and 3.3 per 100 person-years, respectively. When patients with a TTR < 65% were compared with those with TTR ≥ 65%, the adjusted hazard ratios (aHR) for the increased risks of ischemic stroke/TIA, major bleeding, ICH, and death were 3.07, 1.90, 2.34, and 2.11, respectively. Conclusion: Poor TTR control is associated with adverse clinical outcomes in patients with NVAF who were on warfarin. Efforts to ensure good TTR (≥65%) after initiation of warfarin are mandatory to minimize the risk of adverse clinical outcomes.


2019 ◽  
Vol 73 (9) ◽  
pp. 468
Author(s):  
Malini Madhavan ◽  
DaJuanicia N. Holmes ◽  
Jonathan Piccini ◽  
James Freeman ◽  
Gregg Fonarow ◽  
...  

2019 ◽  
Vol Volume 12 ◽  
pp. 151-159 ◽  
Author(s):  
Maria Mariana Silveira ◽  
Leiliandry de Araújo Melo ◽  
Filipe Gomes ◽  
Leonardo José Andrade ◽  
Isabela Serur ◽  
...  

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii13-iii13
Author(s):  
Juan Jesus Carrero ◽  
Alessandro Gasparini ◽  
Staffan Eliasson ◽  
Marie Evans ◽  
Leif Friberg ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document